Is ovarian hyperstimulation syndrome associated with a poor obstetric outcome?

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 107, Issue 8, 2000, Pages 943-946

  Mathur, R S ^a   Jenkins, J M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FEMALE; HUMAN; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; NOTE; OVARY DISEASE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; SPONTANEOUS ABORTION;

BIRTH WEIGHT; FEMALE; FERTILIZATION IN VITRO; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RISK FACTORS; TREATMENT OUTCOME;

EID: 0033916372     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2000.tb10393.x     Document Type: Note

References (18)

1. Human Fertilisation and Embryology Authority. The Interim Patients' Guide to DI, in vitro Fertilisation Clinics. London: HFEA, 1998: 21.
2. Abramov Y, Elchalal U, Schenker JG. An ‘epidemic’ of severe ovarian hyperstimulation syndrome: a price we have to pay Hum Reprod 1999; 14: 2181–2183.
3. Abramov Y, Elchalal U, Schenker JG. Obstetric outcome of in vitro fertilized pregnancies complicated by severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril 1998; 78: 1070–1076.
4. Asch RH, Li H, Balmaceda JP, Weckstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high-risk groups. Hum Reprod 1991; 6: 1395–1399.
5. Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome—syndrome views and ideas. Hum Reprod 1997; 12: 1129–1137.
6. Mathur RS, Bansal AS, Jenkins JM. The probable role of the immune system in the pathogenesis of ovarian hyperstimulation syndrome. Hum Reprod 1997; 12, 2629–2634.
7. Raghupathy R. Th-1 type immunity is incompatible with successful pregnancy. Immunol Today 1997; 18: 478–482.
8. MacDougall MJ, Tan SL, Jacobs HS. In-vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod 1992; 7: 597–600.
9. Balen AH, Tan S-L, MacDougall J, Jacobs HS. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 1993; 8: 959–964.
10. Engmann L, Maconochie N, Sladkevicius P, Bekir J, Campbell S, Tan S-L. The outcome of in-vitro fertilization treatment in women with sonographic evidence of polycystic ovarian disease. Hum Reprod 1999; 14: 167–171.
11. Chen G, Wilson R, Wang SH, Zheng HZ, Walker JJ, McKillop JH. Tumour necrosis factor-alpha (TNF-alpha) gene polymorphism and expression in pre-eclampsia. Clin Exp Immunol 1996; 104: 154–159.
12. Mathur RS, Joels LA, Jenkins JM. Ovarian hyperstimulation syndrome may be more likely if multiple pregnancy occurs following assisted conception. Acta Genet Med Gemellol 1995; 44: 233–235.
13. Maksheed M, Al-Sharhan M, Egbase P, Al-Essa M, Grudzinskas JG. Maternal and perinatal outcomes of multiple pregnancy following in vitro fertilisation-ET. Int J Gynecol Obstet 1998; 61: 155–163.
14. Chen C-D, Wu M-Y, Chao K-H, Ho H-N, Yang Y-S. Serum estradiol level and oocyte number in predicting severe ovarian hyperstimulation syndrome. J Formos Med Assoc 1997; 96: 829–834.
15. Caspi E, Ronen J, Schreyer P, Goldberg MD. The outcome of pregnancy after gonadotrophin therapy. Br J Obstet Gynaecol 1976; 83: 967–973.
16. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 1978; 30: 255–268.
17. Rabau E, David A, Serr DM, Maschiach S, Lunenfeld B. Human menopausal gonadotrophins for anovulation and sterility. Results of 7 years of treatment. Am J Obstet Gynecol 1967; 98: 92–98.
18. Edwards RG, Lobo RA, Bouchard P. Why delay the obvious need for milder forms of ovarian stimulation Hum Reprod 1997; 12: 399–401.